컨텐츠 바로가기
회사소개
회사연혁
찾아오시는길
파이프라인
파이프라인 개요
BAL0891
SJ-600 Series
펙사벡 (JX-594)
JX-900 Series
핵심기술
GEEV®플랫폼
SOLVE® 플랫폼
논문
제약사업부
제품소개
파트너십
글로벌 파트너십
IR/PR
공지 & 뉴스
공고
공시
주가정보
문의하기
자회사소개
신라젠 바이오
신라젠 사이트맵
회사소개
회사연혁
찾아오시는 길
파이프라인
파이프라인 개요
BAL0891
SJ-600 Series
펙사벡 (JX-594)
JX-900 Series
핵심기술
GEEV®플랫폼
SOLVE® 플랫폼
논문
제약사업부
연구현황
제품소개
파트너십
글로벌 파트너십
IR/PR
공지 & 뉴스
공고
공시
주가정보
문의하기
자회사소개
신라젠 바이오
KOR
|
ENG
KOR
KOR
ENG
Targeting, Attacking, and Eradicating Cancers®
TOP
핵심기술
회사소개
핵심기술
파이프라인
제약사업부
파트너십
IR/PR
자회사소개
논문
GEEV® 플랫폼
SOLVE® 플랫폼
논문
논문
총
17
건 ˙
1
/
2
Page
검색어 입력
검색하기 실행 버튼
포스터
전임상
임상
Pre-treatment risk stratification of BAL0891-associated neutropenia to support risk-adapted supportive care: a pooled phase 1 analysis
ENA 2026
Poster
NO
17
Safety and efficacy of BAL0891 as monotherapy and in combination with paclitaxel in a phase I study of advanced solid tumors
ESMO2026
Poster
NO
16
Dual TTK/PLK1 Inhibition Combined with G-CSF Treatment Synergistically Suppresses Metastatic Progression in Triple-Negative Breast Cancer
AACR 2026
Poster
NO
15
Optimizing Immunomodulation of BAL0891, a TTK/PLK1 Dual Inhibitor, to Enhance Synergy with Immune Checkpoint Blockade Using a Biomimetic Tumor Microenvironment Platform and Pharmacometric Modeling
SITC 2025
Poster
NO
14
A Phase 1 study of mitotic checkpoint inhibitor BAL0891 in combination with Tislelizumab (anti-PD-1 antibody) in patients with advanced soild tumors
SITC 2025
Poster
NO
13
Evaluation of the Antitumor Effects of a Dual TTK/PLK1 Inhibitor in Patient-Derived Gastric Cancer Organoids from Malignant Fluids
AOS 2025
Poster
NO
12
TTK/PLK1 Dual Antagonist BAL0891 Synergizes with Pembrolizumab in a Vascularized 3D Tumor Microenvironment Model
AACR 2025
Poster
NO
11
Profiling Patient Response to TTK/PLK1 Dual Antagonist BAL0891 Using 3D Patient-derived Organoid Model in a Microphysiological System
AACR 2025
Poster
NO
10
BAL0891 as a dual kinase inhibitor inducing anti-tumor immunity: A promising partner for immume checkpoint inhibitors
AACR 2025
Poster
NO
9
PB192 Spatial Analysis of Tumor-infiltrating Lymphocytes in mRCC Patients Treated with Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) and cemiplimab (REGN2810; Anti-PD-1)
EORTC-NCI-AACR 2024
Poster
NO
8
1
2